The U.S. prostate cancer biomarkers market size was estimated at USD 1.7 billion in 2024 and is expected to grow at a CAGR of 14.74% from 2025 to 2033. The market growth is driven by the rising prevalence of prostate cancer, awareness around early detection, and adoption of precision diagnostics. Advancements in liquid biopsy, genomics, and non-invasive biomarker technologies are enhancing screening accuracy and patient stratification. Additionally, the rising demand for personalized treatment planning, along with favorable reimbursement frameworks for diagnostic tests such as PSA, PCA3, and gene-expression panels (e.g., Decipher, Oncotype DX), is further accelerating market growth. Strategic collaborations and continuous R&D investment are also expanding the biomarker pipeline and commercial availability.
Prostate cancer is one of the most prevalent malignancies affecting men in the United States. According to the American Cancer Society, 1 in 8 men will be diagnosed with the disease in their lifetime. In 2022 alone, an estimated 268,500 new cases were reported, with approximately 34,500 deaths, making it the second leading cause of cancer death among American men. Today, over 3.1 million men in the U.S. are living with prostate cancer. This substantial patient population, along with limitations in traditional diagnostics such as PSA testing, which lacks specificity to distinguish between benign and malignant conditions, has created strong demand for novel biomarkers that can enable earlier detection, improved risk stratification, and treatment personalization.
This product will be delivered within 1-3 business days.
Prostate cancer is one of the most prevalent malignancies affecting men in the United States. According to the American Cancer Society, 1 in 8 men will be diagnosed with the disease in their lifetime. In 2022 alone, an estimated 268,500 new cases were reported, with approximately 34,500 deaths, making it the second leading cause of cancer death among American men. Today, over 3.1 million men in the U.S. are living with prostate cancer. This substantial patient population, along with limitations in traditional diagnostics such as PSA testing, which lacks specificity to distinguish between benign and malignant conditions, has created strong demand for novel biomarkers that can enable earlier detection, improved risk stratification, and treatment personalization.
U.S. Prostate Cancer Biomarkers Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-markets from 2021 to 2033. For this study, the analyst has segmented the U.S. prostate cancer biomarkers market report based on type, application, and end-use:Type Outlook (Revenue, USD Million, 2021 - 2033)
- Genetic Biomarkers
- Protein Biomarkers
- Cell-based Biomarkers
- Metabolomic Biomarkers
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Screening and Early Detection
- Diagnosis and Risk Stratification
- Prognosis and Treatment Monitoring
- Companion Diagnostics
End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals and Diagnostic Laboratories
- Academic and Research Institutes
- Biopharmaceutical Companies
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 U.S. Prostate Cancer Biomarkers Market Variables, Trends, And Scope
Chapter 4 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By Type, 2021 - 2033 (USD Million)
Chapter 5 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By Application, 2021 - 2033 (USD Million)
Chapter 6 U.S. Prostate Cancer Biomarkers Market: Segment Analysis, By End USE, 2021 - 2033 (USD Million)
Chapter 7 U.S. Prostate Cancer Biomarkers Market: Competitive Analysis
List of Tables
List of Figures
Companies Mentioned
- Exact Sciences Corporation
- Myriad Genetics, Inc.
- Bio-Techne
- ExoDx
- OPKO Health, Inc.
- mdxhealth
- Veracyte, Inc.
- Beckman Coulter, Inc.
- Nucleix
- DiaCarta
